Hyperthermia Cancer Treatment Market

Market Outlook for Hyperthermia Cancer Treatment

The global hyperthermia cancer treatment market is expected to expand at a healthy CAGR of approximately 6% over the 2021 to 2031 assessment period. Most of the revenue will be contributed by the sale of microwave hyperthermia cancer treatment devices.

Cancer treatment around the world is experiencing a paradigm shift, with healthcare providers opting for various non-invasive diagnostic and therapeutic approaches so as to minimize patient discomfort and improve clinical outcomes. This has boded well for the hyperthermia cancer treatment providers.Treatment for breast and prostate cancers are anticipated to generate maximum revenue pools, owing to their high prevalence rates. Furthermore, microwave hyperthermia cancer devices shall experience a major upswing.

In its new study, consulting firm Fact.MR offers insights about key factors driving demand for hyperthermia cancer treatment. The report tracks the global sales of the hyperthermia cancer treatment market in 20+ high-growth markets, along with analyzing the impact COVID-19 has had on the healthcare domain in general, and demand for hyperthermia treatment for cancer in particular.

How Do Historical and Future Projections Compare?

The market experienced credible growth in the historical period, largely driven by extensive applications in breast cancer treatment. Various technologies, including high intensity focused ultrasound (HIFU) and deep tissue & regional perfusion, have been deployed to eradicate this disease.

The market remain largely consistent throughout the COVID-19 pandemic, as cancer patients acquired top priority amid feared complications and casualties induced by possible infection. According to Fact.MR, the market is slated to reach over US$ 250 million by 2031, expanding at a healthy CAGR of nearly 6%.

How is Rising Cancer Burden Catalyzing Demand for Hyperthermia Treatment for Cancer?

Rise in prevalence and incidence of cancers such as breast, liver, soft tissue sarcoma, head & neck tumors, prostate cancer, and others drives demand for hyperthermia cancer treatment. According to the National Cancer Institute (NCI), an estimated 1.8 million cases are expected to be diagnosed in the U.S. in 2020, with prostate, lung, and colorectal cancer comprising 43% of the total cancer cases in men.

More than 60% of the world’s new cancer cases occur in Africa, Asia, and Central and South America, and 70% of the total cancer deaths globally occur in these regions. Most of these cancers impact the geriatrics, with around two out of five cases occurring amongst adults above 60 years of age.

Why is There Increased Preference for High Intensity Focused Ultrasound (HIFU)?

Therapeutic applications of heat is highly effective in cancer treatment. Hence companies are augmenting production capacities in high quality heating equipment to enable precise thermal dosimetry. This has generated innovations in antennas and power delivery systems that provide adequate quality assurance for the treatment of cancer patients.

High intensity focused ultrasound (HIFU), nanoparticle heating, and scanned focused ultrasound (SFUS) techniques are broadening revenue streams for companies involved in hyperthermia cancer treatment. As such, ultrasound hyperthermia devices are predicted to dominate the second highest revenue among all device types in the market.

Country-wise Analysis

Why is the U.S. a Highly Promising Market for Hyperthermia Cancer Treatment?

According to the National Cancer Institute, the rate of new cancers is 442.4 per 100,000 men and women per year, with mortality estimated at 158.3 per 100,000 men and women annually. Approximately, 39.5% of patients will be diagnosed with cancer at some point of their lives. The number of survivors is likely to reach 22.2 million by 2030.

Consequently, healthcare providers are seeking to integrate advanced treatment options, which is widening the scope for hyperthermia cancer treatment. The treatment is administered by the Pyrexar-500 that delivers heat energy directly into the cancerous tumor at temperatures between 104-113 degrees Fahrenheit which destroys malignant tumor cells, while minimizing damage to surrounding healthy tissue.

Do Prospects for Hyperthermia Cancer Treatment Solution Providers Look Good in the U.K.?

In recent years, medical practitioners have been tilting towards non-invasive cancer treatment approaches, a trend which has generated immense opportunities for hyperthermia treatment.

Prominent player Breakspear Medical is the first facility to offer hyperthermia cancer treatment. Its IRATHERM® 1000 whole-body hyperthermia bed not only raises body surface temperature, but also the core temperature which can have a major therapeutic effect. Besides cancer treatment, it is also useful for a host of other ailments, including arterial hypertension and rheumatic diseases.

Category-wise Insights

Why are Sales of Microwave Devices Picking Up Pace?

Microwave hyperthermia cancer treatment devices shall capture an attractive revenue share, attributed to its ability to transmit energy from antenna to cancer cells without being impeded in fat layers. It is expected to yield over two-fifths of the revenue through 2031.

Simultaneously, ultrasound devices are expected to garner significant momentum, owing to its non-invasive nature. Several manufacturers are augmenting their operations to include more ultrasound devices.

How is Breast Cancer Treatment Stimulating Overall Market Growth?

Globally, breast cancer is the most prevalent type of cancer, affecting over 2 million women as of 2018. Moreover, it is the most prevalent cancer type across the world. Hence, key manufacturers are developing highly advanced hyperthermic treatment approaches to cure this deadly disease.

PYREXAR Medical is a pioneer in this regard, offering the BSD-500 portable superficial hyperthermia treatment device designed for palliative treatment of certain tumors, including breast cancer.

Competitive Landscape

Introducing technologically advanced products and strengthening distribution networks form the core expansion strategy of prominent market players. Some notable developments are as follows:

• In February 2021, innoMedicus Ltd. published a study in JAMA Oncology, establishing that non-contrast MRI yields better diagnosis of prostate cancer
• Likewise, Gamida Cell announced a US$ 75 million financing with Highbridge Capital Management to further its Omidubicel and GDA-201 clinical development

Report Scope

Attribute	Details
Forecast Period	2021-2031
Historical Data Available for	2016-2020
Market Analysis	US$ Mn for Value & ‘000 Units for Volume
Key Regions Covered	North America Europe Asia-Pacific Latin America Middle East & Africa
Key Countries Covered	US Canada UK Germany France Spain Italy China India Japan Australia & New Zealand GCC South Africa Brazil Mexico
Key Segments Covered	Device Type Treatment Method Application End-User
Key Companies Profiled	PYREXAR Medical Celsius42 GmbH Hydrosun GmbH Oncotherm Kft. Andromedic S.r.l. Yamamoto Vinita Co. Ltd Chongqing Haifu Medical Technology Co. Ltd. innoMedicus Ltd. Gamida-Cell Ltd. RanD
Customization & Pricing	Available upon Request

Key Market Segments Covered

• Device

  • Infrared Devices for Hyperthermia Cancer Treatment
  • Magnetic Hyperthermia Devices
  • Ultrasound Hyperthermia Devices
  • Microwave Devicesfor Hyperthermia Cancer Treatment
  • Others

• Treatment Method

  • Loco-regional Method
  • External & Interstitial
  • Intraluminal or Endocavitary Methods
  • Continuous Hyperthermic Peritoneal Perfusion (CHPP)
  • Deep Tissue & Regional Perfusion
  • Whole Body

• Application

  • Breast Cancer
  • Liver Cancer
  • Soft Tissue Sarcoma
  • Head & Neck Tumors
  • Prostate Cancer
  • Others

• End User

  • for Hyperthermia Cancer Treatment at Hospitals & Specialty Clinics
  • for Hyperthermia Cancer Treatment at Ambulatory Surgical Centers
  • Others

• Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia & New Zealand
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of MEA